Sinovac has reported that the single-agent clinical 1b cohort expansion trial for Pidnarulex (CX-5461), its自主研发新药for late-stage solid tumors with BRCA2/PALB2 gene mutations, has completed patient enrollment. The company anticipates releasing the clinical trial report in the first quarter of 2027.